Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) FCF Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed FCF Margin for 5 consecutive years, with 53.1% as the latest value for Q4 2025.

  • Quarterly FCF Margin changed N/A to 53.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24.76% through Dec 2025, changed N/A year-over-year, with the annual reading at 24.58% for FY2025, 2998148.0% down from the prior year.
  • FCF Margin for Q4 2025 was 53.1% at Soleno Therapeutics, down from 65.89% in the prior quarter.
  • The five-year high for FCF Margin was 2406.83% in Q1 2025, with the low at 38.76% in Q2 2025.